Group 1 - The core viewpoint of the article highlights that funds focused on innovative pharmaceuticals have seen significant gains, with some funds increasing over 61% in the first half of the year [1] - The top-performing funds include several that are primarily invested in innovative drugs, with the highest return being 86.48% for the fund "汇添富音港优势精选A" [1] - Other notable funds in the top 16 also show strong performance, with returns ranging from 61.77% to 83.15% [1] Group 2 - The article suggests that innovative drugs can be pursued when the market declines, indicating a potential buying opportunity [2] - The "广发成长领航一年持有A" fund has a significant portion of its holdings in new consumer concepts, with major investments in companies like 泡泡玛特 and 老铺黄金 [3] - The fund manager 吴远怡 has demonstrated strong performance across various products, with most showing commendable returns [4] Group 3 - The historical performance of the "广发科技创新" fund shows a maximum drawdown of -53%, indicating high volatility [5] - Overall, the funds discussed are characterized by high volatility and significant drawdowns, making them more suitable for investors willing to buy during market dips [7] - The article emphasizes that these funds may not be suitable for low-risk investors due to their performance characteristics [7]

Group 1 - The market has experienced significant structural trends in the first half of the year, driven by policy support and the rise of AI, with themes like humanoid robots, innovative drugs, and new consumption performing well [2] - The average return of 4,434 active equity funds was 6.89% in the first half of the year, excluding newly established funds [2] - Jiashi Fund ranked third among large companies in absolute return for equity funds over the past two years and one year, with over 50 of its products achieving returns exceeding 30% in the past year [2] Group 2 - Jiashi Fund's active equity product, Jiashi Huirong Selected A, achieved a return of 69.56% over the past two years, ranking first among 804 comparable active stock open-end funds [3] - Several Jiashi Fund products, including Jiashi Innovation Pioneer A/C and Jiashi Green Theme A/C, reported returns exceeding 50% in the past year, focusing on core sectors like technology, manufacturing, and new energy [3] Group 3 - Jiashi Fund's "Super ETF" products have performed well in the structural market, with the Sci-Tech Chip ETF (588200) showing a 66.51% increase over the past year [3] - Other ETFs, such as the Hang Seng Medical ETF and Internet ETF, also reported returns exceeding 60% in the same period [3] Group 4 - Jiashi Fund has developed a comprehensive "Sci-Tech Full Jiashi Barrel" series of ETFs targeting high-growth sectors, including various thematic ETFs in the technology industry [4] - The launch of the first batch of Sci-Tech Bond ETFs aims to broaden financing channels for innovative companies and provide a transparent and efficient investment tool for clients [4]

Core Insights - The A-share market in the first half of 2025 exhibited a distinct structural trend, with pharmaceutical and biotechnology-themed funds dominating performance rankings [1] - Over 120 funds were liquidated during this period, indicating significant market shifts [1] Performance Summary Top Performing Funds - The top ten stock funds saw significant returns, with the leading fund, Huaan Pharmaceutical Bio A, achieving a return of 66.44% [2] - Other notable performers included Jiashi Huron Selected A (60.26%) and Ping An Pharmaceutical Selected A (58.80%) [2] - The average return of the top ten funds was driven primarily by smaller, actively managed funds, highlighting their flexibility in capturing rapid market movements [5] Underperforming Funds - The worst-performing funds were led by Jianxin China Manufacturing 2025 A, which recorded a decline of 14.68% [4] - Other funds in the bottom tier included Huaxia Advantage Selected and Great Wall Quantitative Selected A, both with declines exceeding 12% [4] - The coal and photovoltaic sectors faced significant downward pressure, with several funds in these categories showing substantial losses [4] Sector Analysis Pharmaceutical and Biotechnology - The pharmaceutical and biotechnology sectors have seen a resurgence after a prolonged adjustment period, driven by improved valuations and supportive policies [5] - The global and domestic biotech investment climate is recovering, contributing to the strong performance of related funds [5] Coal and Photovoltaic Industries - The coal industry is experiencing a shift in supply-demand dynamics, leading to downward pressure on valuations due to economic restructuring and accelerated energy transitions [5] - The photovoltaic sector is facing intensified competition and concerns over overcapacity, impacting short-term profitability and stock performance [5] Market Outlook - The A-share market is expected to show a trend of gradual upward movement in the second half of 2025, supported by increased participation from public funds and favorable policies [6] - However, significant differentiation among sectors may lead to rebalancing pressures, particularly in pharmaceuticals and biotechnology [6] - Investors are advised to analyze macroeconomic trends and industry policies to identify opportunities amidst market volatility [6]

Core Viewpoint - The article highlights a bullish trend in both equity and bond markets in Q2 2025, driven by increased market liquidity and favorable government policies encouraging long-term investments. The performance of various fund categories, particularly technology and QDII equity funds, has been notably strong, with significant returns over the past three years. Fund Performance Section 1.1 Fund Classification Rankings - The top-performing ordinary equity funds over the past three years include: - Jin Ying Technology Innovation A with a return of 75.05% and a maximum drawdown of -38.68% [3] - Jia Shi Hu Rong Selected A with a return of 64.08% and a maximum drawdown of -38.79% [3] - Jing Shun Chang Cheng Hu Gang Shen Selected A with a return of 57.71% and a maximum drawdown of -14.73% [3] 1.2 Mixed Equity Fund Rankings - The leading mixed equity funds include: - Hua Xia North Exchange Innovation with a return of 175.64% and a maximum drawdown of -30.93% [5] - Hui Tian Fu North Exchange Innovation with a return of 111.39% and a maximum drawdown of -27.37% [5] - Wan Jia North Exchange Wisdom Selection with a return of 94.03% and a maximum drawdown of -28.03% [5] 1.3 QDII Equity Fund Rankings - The top QDII equity funds are: - Yi Fang Da Biao Pu Information Technology A with a return of 119.55% and a maximum drawdown of -25.54% [19] - Hua Xia Nasdaq 100 ETF with a return of 108.00% and a maximum drawdown of -22.41% [19] - Hua An Germany (DAX) ETF with a return of 106.74% and a maximum drawdown of -14.76% [19] 1.4 Performance of Bond Funds - The performance of bond funds shows: - The Wan De Short-term Pure Bond Fund Index and the Wan De Medium-term Pure Bond Fund Index increased by 0.64% and 0.95%, respectively, reaching new highs [1] - The top-performing mixed bond funds include Hua Xia Pan Tai A with a return of 30.18% and a maximum drawdown of -7.64% [7] 1.5 Investment Trends - The article notes that the ETF has become a preferred tool for asset allocation, with many products frequently appearing on performance lists, indicating their investment value [1]